|
US4642316A
(en)
*
|
1985-05-20 |
1987-02-10 |
Warner-Lambert Company |
Parenteral phenytoin preparations
|
|
US6071923A
(en)
*
|
1994-09-16 |
2000-06-06 |
Bar-Ilan University |
Retinoyloxy aryl-substituted alkylene butyrates useful for the treatment of cancer and other proliferative diseases
|
|
US20020025921A1
(en)
*
|
1999-07-26 |
2002-02-28 |
Petito George D. |
Composition and method for growing, protecting, and healing tissues and cells
|
|
WO2000021979A2
(en)
*
|
1998-10-13 |
2000-04-20 |
Fujisawa Pharmaceutical Co., Ltd. |
Cyclic tetrapeptide and their use as histone deacetylase inhibitor
|
|
US20070148228A1
(en)
*
|
1999-02-22 |
2007-06-28 |
Merrion Research I Limited |
Solid oral dosage form containing an enhancer
|
|
EP1179541B1
(en)
*
|
1999-04-28 |
2004-06-16 |
Board Of Regents, The University Of Texas System |
Compositions and methods for cancer treatment by selectively inhibiting VEGF
|
|
KR20100035666A
(ko)
*
|
1999-11-23 |
2010-04-05 |
메틸진 인크. |
히스톤 디아세틸라제의 억제제
|
|
CA2423868C
(en)
*
|
2000-09-29 |
2011-06-07 |
Prolifix Limited |
Carbamic acid compounds comprising an amide linkage as hdac inhibitors
|
|
GB0023983D0
(en)
*
|
2000-09-29 |
2000-11-15 |
Prolifix Ltd |
Therapeutic compounds
|
|
EP2292593A3
(en)
*
|
2000-09-29 |
2011-05-25 |
TopoTarget UK Limited |
Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
|
|
WO2002074298A1
(en)
*
|
2001-03-21 |
2002-09-26 |
Ono Pharmaceutical Co., Ltd. |
Il-6 production inhibitors
|
|
MXPA04001253A
(es)
*
|
2001-08-09 |
2004-06-03 |
Ono Pharmaceutical Co |
Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo.
|
|
US6897220B2
(en)
*
|
2001-09-14 |
2005-05-24 |
Methylgene, Inc. |
Inhibitors of histone deacetylase
|
|
RU2301666C2
(ru)
*
|
2002-01-11 |
2007-06-27 |
Маттиас Рат |
Обладающий питательными свойствами фармацевтический состав на основе полифенолов и его использование при лечении рака
|
|
US20030235588A1
(en)
*
|
2002-02-15 |
2003-12-25 |
Richon Victoria M. |
Method of treating TRX mediated diseases
|
|
US20050288227A1
(en)
*
|
2002-02-15 |
2005-12-29 |
Marks Paul A |
Use of thioredoxin measurements for diagnostics and treatments
|
|
US20040132825A1
(en)
*
|
2002-03-04 |
2004-07-08 |
Bacopoulos Nicholas G. |
Methods of treating cancer with HDAC inhibitors
|
|
US20070060614A1
(en)
*
|
2002-03-04 |
2007-03-15 |
Bacopoulos Nicholas G |
Methods of treating cancer with hdac inhibitors
|
|
MXPA04008577A
(es)
*
|
2002-03-04 |
2005-07-13 |
Aton Pharma Inc |
Metodos para inducir diferenciacion terminal.
|
|
US7148257B2
(en)
*
|
2002-03-04 |
2006-12-12 |
Merck Hdac Research, Llc |
Methods of treating mesothelioma with suberoylanilide hydroxamic acid
|
|
WO2003087066A1
(en)
*
|
2002-04-11 |
2003-10-23 |
Sk Chemicals, Co., Ltd. |
α,β-UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS
|
|
JP2005530734A
(ja)
*
|
2002-04-15 |
2005-10-13 |
スローン − ケッタリング インスティチュート フォー キャンサー リサーチ |
癌の処置のための併用療法
|
|
US8883148B2
(en)
*
|
2002-04-26 |
2014-11-11 |
Asan Laboratories Company (Cayman), Limited |
Prevention of joint destruction
|
|
US20080004311A1
(en)
*
|
2002-11-12 |
2008-01-03 |
Alcon, Inc. |
Histone deacetylase inhibitors for treating degenerative diseases of the eye
|
|
WO2004064727A2
(en)
*
|
2003-01-16 |
2004-08-05 |
Georgetown University |
Method of cancer treatment using hdac inhibitors
|
|
US7375228B2
(en)
*
|
2003-03-17 |
2008-05-20 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
|
US20040220242A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Leland Shapiro |
Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions
|
|
EP1491188A1
(en)
*
|
2003-06-25 |
2004-12-29 |
G2M Cancer Drugs AG |
Topical use of valproic acid for the prevention or treatment of skin disorders
|
|
HRP20060080A2
(en)
*
|
2003-08-26 |
2006-07-31 |
Sloan-Kettering Institute For Cancer Research |
Method of treating cancer with hdac inhibitors
|
|
WO2005052143A2
(de)
*
|
2003-11-14 |
2005-06-09 |
Per Sonne Holm |
Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung
|
|
EP1689445B1
(de)
*
|
2003-11-14 |
2015-02-25 |
Per Sonne Holm |
Neue verwendung von adenoviren und dafür codierende nukleinsäuren
|
|
GB0401876D0
(en)
*
|
2004-01-28 |
2004-03-03 |
Vereniging Het Nl Kanker I |
New use for cancer antigen
|
|
CA2557568C
(en)
*
|
2004-02-27 |
2014-05-27 |
Jane Trepel |
Pharmacodynamic assays using flow cytometry
|
|
EP1591109B1
(en)
*
|
2004-04-30 |
2008-07-02 |
TopoTarget Germany AG |
Formulation comprising histone deacetylase inhibitor exhibiting biphasic release
|
|
WO2006014024A1
(ja)
*
|
2004-08-06 |
2006-02-09 |
Ono Pharmaceutical Co., Ltd. |
精神神経系疾患治療剤
|
|
CN101001851B
(zh)
*
|
2004-08-09 |
2011-04-20 |
安斯泰来制药有限公司 |
具有作为组蛋白脱乙酰酶(hdac)抑制剂的活性的羟基酰胺化合物
|
|
US8889742B2
(en)
*
|
2004-11-30 |
2014-11-18 |
The Trustees Of The University Of Pennsylvania |
Use of HDAC and/or DNMT inhibitors for treatment of ischemic injury
|
|
US20090232800A1
(en)
*
|
2004-12-31 |
2009-09-17 |
Per Sonne Holm |
E1-minus adenoviruses and use thereof
|
|
EP1845973B1
(en)
*
|
2005-01-21 |
2015-08-12 |
Astex Therapeutics Limited |
Pharmaceutical compounds
|
|
NZ589276A
(en)
*
|
2005-02-03 |
2012-06-29 |
Topotarget Uk Ltd |
Combination therapies using hdac inhibitors and erlotinib (tarceva)
|
|
US20060229237A1
(en)
*
|
2005-04-07 |
2006-10-12 |
Yih-Lin Chung |
Treatment of gastrointestinal distress
|
|
GB0509225D0
(en)
*
|
2005-05-05 |
2005-06-15 |
Chroma Therapeutics Ltd |
Inhibitors of enzymatic activity
|
|
SI1901729T1
(sl)
*
|
2005-05-13 |
2012-05-31 |
Topotarget Uk Ltd |
Farmacevtske formulacije HDAC inhibitorjev
|
|
EP1743654A1
(en)
*
|
2005-07-15 |
2007-01-17 |
TopoTarget Germany AG |
Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
|
|
AU2006283677A1
(en)
*
|
2005-08-19 |
2007-03-01 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Topical formulations of histone deacetylase inhibitors and methods of using the same
|
|
CA2621406A1
(en)
*
|
2005-09-07 |
2007-03-15 |
Plexxikon, Inc. |
Pparactive compounds
|
|
CA2627923C
(en)
*
|
2005-11-10 |
2016-01-12 |
Topotarget Uk Limited |
Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer
|
|
US8445198B2
(en)
*
|
2005-12-01 |
2013-05-21 |
Medical Prognosis Institute |
Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
|
|
US8530493B2
(en)
*
|
2006-02-22 |
2013-09-10 |
4Sc Ag |
Indolopyridines as Eg5 kinesin modulators
|
|
AU2007217562A1
(en)
*
|
2006-02-22 |
2007-08-30 |
4Sc Ag |
Indolopyridines as EG5 kinesin modulators
|
|
EP1839656A1
(en)
*
|
2006-03-31 |
2007-10-03 |
TopoTarget Germany AG |
Use of valproic acid for the topical treatment of mild to moderate acne vulgaris
|
|
US20090142337A1
(en)
*
|
2006-05-08 |
2009-06-04 |
Astex Therapeutics Limited |
Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment
|
|
WO2007146234A2
(en)
*
|
2006-06-09 |
2007-12-21 |
Merrion Research Ii Limited |
Solid oral dosage form containing an enhancer
|
|
US8338482B2
(en)
*
|
2006-07-20 |
2012-12-25 |
Wisconsin Alumni Research Foundation |
Modulating notch1 signaling pathway for treating neuroendocrine tumors
|
|
US20080242648A1
(en)
*
|
2006-11-10 |
2008-10-02 |
Syndax Pharmaceuticals, Inc., A California Corporation |
COMBINATION OF ERa+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
|
|
US8796330B2
(en)
*
|
2006-12-19 |
2014-08-05 |
Methylgene Inc. |
Inhibitors of histone deacetylase and prodrugs thereof
|
|
US7915245B2
(en)
*
|
2007-02-01 |
2011-03-29 |
The Board Of Regents Of The University Of Texas System |
Methods and compositions of trail-death receptor agonists/activators
|
|
WO2008101121A2
(en)
*
|
2007-02-14 |
2008-08-21 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions relating to promoter regulation by muc1 and klf proteins
|
|
WO2008136838A1
(en)
*
|
2007-05-04 |
2008-11-13 |
Trustees Of Dartmouth College |
Novel amide derivatives of cddo and methods of use thereof
|
|
GB2454118B
(en)
*
|
2007-06-06 |
2010-06-02 |
Univ Maryland |
Hdac inhibitors and hormone targeted drugs for the treatment of cancer
|
|
WO2009146034A2
(en)
*
|
2008-03-31 |
2009-12-03 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors and methods of use thereof
|
|
US20090270497A1
(en)
*
|
2008-04-24 |
2009-10-29 |
Pharmacyclics, Inc. |
Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
|
|
WO2009137649A2
(en)
*
|
2008-05-07 |
2009-11-12 |
The Trustees Of The University Of Pennsylvania |
Methods for treating thyroid cancer
|